Boston Scientific Corp (NYSE: BSX)

$64.57 ▲ +5.05 (+8.48%)

As of Apr 22, 2026 03:35 PM

Sector: Healthcare Industry: Medical Devices CIK: 0000885725

Market Cap 88.11 Bn

P/E 30.21

P/S 4.39

Div. Yield 0.00

ROIC (Qtr) 0.10

Total Debt (Qtr) 11.44 Bn

Revenue Growth (1y) (Qtr) 15.90

Add ratio to table...

About

Boston Scientific Corp is a global developer, manufacturer, and marketer of medical devices used in various interventional medical specialties. The company has been advancing the practice of less-invasive medicine for over 45 years, providing alternatives to surgery and other traumatic medical procedures. Boston Scientific's mission is to transform lives through innovative medical solutions that improve the health of patients worldwide. The company's portfolio includes a broad range of high-performance solutions designed to address unmet patient...

Boston Scientific Corp is a global developer, manufacturer, and marketer of medical devices used in various interventional medical specialties. The company has been advancing the practice of less-invasive medicine for over 45 years, providing alternatives to surgery and other traumatic medical procedures. Boston Scientific's mission is to transform lives through innovative medical solutions that improve the health of patients worldwide. The company's portfolio includes a broad range of high-performance solutions designed to address unmet patient needs and reduce healthcare costs.

Boston Scientific generates revenue through the sale of its medical devices, which are used in diagnosing and treating a wide range of diseases and medical conditions. The company's primary products include hemostatic clips, stent systems, single-use scopes, endoluminal surgery products, stone management products, laser systems, prosthetic urology products, hydrogel systems, neuromodulation devices, intravascular imaging systems, vessel preparation technologies, coronary drug-eluting therapies, peripheral vascular therapies, minimally invasive therapies for blood clot removal, injectable treatments for venous reflux, left atrial appendage closure devices, electrophysiology technologies, cardiac rhythm management devices, and interventional oncology products. These products cater to a diverse customer base, including hospitals, clinics, outpatient facilities, and medical offices globally.

• MedSurg: This segment is further divided into Endoscopy, Urology, and Neuromodulation business units. The Endoscopy business unit offers devices for diagnosing and treating gastrointestinal and pancreaticobiliary conditions, including hemostatic clips, stent systems, single-use scopes, and infection prevention products. The Urology business unit provides devices for treating various urological conditions, such as kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, male incontinence, overactive bladder, and pelvic floor disorders. Key products include stone management products, laser systems, prosthetic urology products, hydrogel systems, and products for treating pelvic floor disorders. The Neuromodulation business unit develops devices to treat neurological movement disorders and manage chronic pain, with products like spinal cord stimulators, intraosseous nerve ablation systems, radiofrequency ablation systems, and deep brain stimulation systems.

• Cardiovascular: This segment includes Interventional Cardiology and Vascular Therapies, Watchman, Electrophysiology, Cardiac Rhythm Management, and Interventional Oncology and Embolization business units. The Interventional Cardiology and Vascular Therapies business unit offers technologies for diagnosing and treating complex coronary, peripheral, and venous diseases, including intravascular imaging systems, vessel preparation technologies, coronary drug-eluting therapies, and peripheral vascular therapies. The Watchman business unit provides left atrial appendage closure devices for patients with non-valvular atrial fibrillation. The Electrophysiology business unit develops technologies for diagnosing and treating rate and rhythm disorders of the heart, including pulsed field ablation systems, mapping systems, access solutions, and ablation systems. The Cardiac Rhythm Management business unit offers implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including implantable cardioverter defibrillators, subcutaneous implantable cardiac defibrillators, pacemakers, remote patient management systems, and cardiac monitoring systems. The Interventional Oncology and Embolization business unit develops products to treat various forms of cancer, including radioactive glass microsphere therapy, hepatic arterial infusion systems, cryoablation systems, and embolization devices.

Boston Scientific operates in a highly competitive industry, facing significant competition from global and local competitors. Key competitors include large manufacturers with multiple lines of business and competing products, as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. The company also encounters competition from low-cost manufacturers and non-medical device companies offering alternative therapies. Boston Scientific's competitive advantages lie in its ability to deliver differentiated clinical and economic outcomes, ease of use, comparative effectiveness, reliability, and physician familiarity. The company's success depends on its ability to continue offering innovative, scientifically advanced technologies, attract and retain qualified personnel, protect intellectual property, obtain regulatory and reimbursement approvals, maintain quality systems, and successfully market its products.

Boston Scientific's customers include hospitals, clinics, outpatient facilities, and medical offices in 127 countries worldwide. The company's products are purchased by healthcare providers who typically bill various third-party payers, including government programs and private insurance payers, for the items and services provided to their patients. The company's marketing and sales efforts are directed towards physicians who specialize in the diagnosis and treatment of different medical conditions, as well as key hospital service line administrators. Boston Scientific's net sales are derived from countries where it has direct sales organizations, and it also has a network of distributors and dealers who offer its products in certain countries and markets.

Investment thesis

Bull case

Boston Scientific’s electrophysiology (EP) division reported 35 % organic growth in the fourth quarter, a figure that eclipses the top competitors in the segment. The company’s leadership, while acknowledging the broader EP market is only expanding at about 15 %, maintains that its differentiated product mix and ecosystem will allow it to outpace that growth. Hidden catalysts include the upcoming CHAMPION trial, which, if positive, could elevate the WATCHMAN device from a secondary stroke‑prevention tool to a first‑line alternative to oral anticoagulants, dramatically expanding its potential patient base. The study’s focus on both ischemic and bleeding outcomes aligns with the current reimbursement climate, increasing the likelihood of favorable coverage decisions. Such data would not only boost WATCHMAN sales but also reinforce Boston Scientific’s EP dominance across multiple indications.
The EP portfolio is being enriched by the launch of FARAPOINT and FARAFLEX catheters, along with the OPAL mapping system and a new partnership with Siemens Healthineers for a 4D ICE catheter. These innovations are designed to reduce procedural time, enhance safety, and broaden the range of arrhythmias that can be addressed, from atrial fibrillation to ventricular tachycardia. Boston Scientific’s commitment to ongoing clinical studies, such as the REMATCH AF trial and the FARAPOINT ventricular program, signals a steady stream of future approvals that can capture additional market share. By expanding its product indications, the company is not only diversifying its revenue streams but also reinforcing the value proposition to physicians, who increasingly demand high‑efficiency, single‑procedure solutions. This trajectory positions Boston Scientific to maintain, if not accelerate, its organic growth trajectory in the coming years.
Strategic acquisitions are slated to create a more robust and complementary product ecosystem. The pending acquisition of Penumbra will add high‑growth neurovascular assets, including mechanical thrombectomy systems that serve a rapidly expanding stroke treatment market. Simultaneously, the Valencia acquisition will broaden the company’s presence in pelvic health, adding devices that complement its neuromodulation and urology lines. Successful integration of these assets will open cross‑sell opportunities, deepen its service‑based revenue model, and provide access to new geographic markets and payer networks. By leveraging these acquisitions, Boston Scientific can accelerate time‑to‑market for its integrated care pathways, thereby increasing pricing power and margin resilience.
The company’s operating margin expansion strategy has proven effective, with a 100‑basis‑point lift in 2025 and a targeted 50‑75‑basis‑point increase for 2026. This disciplined approach to cost control, combined with an efficient supply chain and strong pricing leverage, has translated into high free‑cash‑flow conversion and a healthy cash position of $1.96 billion. Such liquidity affords the firm flexibility to fund further acquisitions, sustain R&D pipelines, and pursue strategic share repurchases, all of which can enhance shareholder value. Moreover, the robust margin profile supports the company’s ability to weather short‑term disruptions, such as product withdrawals or regulatory delays, without compromising its long‑term growth strategy.
Boston Scientific is aggressively expanding into high‑growth international markets, notably China and Japan, where it has secured NMPA approval for the FARAWAVE NAV system and obtained persistent AF indications in China. The firm’s domestic EP market, already achieving approximately 80 % PFA penetration, indicates a near‑saturation point that drives clinicians to seek more advanced solutions, such as the newly approved FARAPOINT catheter. These geographic strides diversify the company’s revenue base, reduce dependence on any single market, and provide a buffer against regional economic or regulatory fluctuations. Consequently, the firm is well‑positioned to sustain its growth trajectory even if domestic markets face headwinds.

Boston Scientific’s electrophysiology (EP) division reported 35 % organic growth in the fourth quarter, a figure that eclipses the top competitors in the segment. The company’s leadership, while acknowledging the broader EP market is only expanding at about 15 %, maintains that its differentiated product mix and ecosystem will allow it to outpace that growth. Hidden catalysts include the upcoming CHAMPION trial, which, if positive, could elevate the WATCHMAN device from a secondary stroke‑prevention tool to a first‑line alternative to oral anticoagulants, dramatically expanding its potential patient base. The study’s focus on both ischemic and bleeding outcomes aligns with the current reimbursement climate, increasing the likelihood of favorable coverage decisions. Such data would not only boost WATCHMAN sales but also reinforce Boston Scientific’s EP dominance across multiple indications.
The EP portfolio is being enriched by the launch of FARAPOINT and FARAFLEX catheters, along with the OPAL mapping system and a new partnership with Siemens Healthineers for a 4D ICE catheter. These innovations are designed to reduce procedural time, enhance safety, and broaden the range of arrhythmias that can be addressed, from atrial fibrillation to ventricular tachycardia. Boston Scientific’s commitment to ongoing clinical studies, such as the REMATCH AF trial and the FARAPOINT ventricular program, signals a steady stream of future approvals that can capture additional market share. By expanding its product indications, the company is not only diversifying its revenue streams but also reinforcing the value proposition to physicians, who increasingly demand high‑efficiency, single‑procedure solutions. This trajectory positions Boston Scientific to maintain, if not accelerate, its organic growth trajectory in the coming years.
Strategic acquisitions are slated to create a more robust and complementary product ecosystem. The pending acquisition of Penumbra will add high‑growth neurovascular assets, including mechanical thrombectomy systems that serve a rapidly expanding stroke treatment market. Simultaneously, the Valencia acquisition will broaden the company’s presence in pelvic health, adding devices that complement its neuromodulation and urology lines. Successful integration of these assets will open cross‑sell opportunities, deepen its service‑based revenue model, and provide access to new geographic markets and payer networks. By leveraging these acquisitions, Boston Scientific can accelerate time‑to‑market for its integrated care pathways, thereby increasing pricing power and margin resilience.
The company’s operating margin expansion strategy has proven effective, with a 100‑basis‑point lift in 2025 and a targeted 50‑75‑basis‑point increase for 2026. This disciplined approach to cost control, combined with an efficient supply chain and strong pricing leverage, has translated into high free‑cash‑flow conversion and a healthy cash position of $1.96 billion. Such liquidity affords the firm flexibility to fund further acquisitions, sustain R&D pipelines, and pursue strategic share repurchases, all of which can enhance shareholder value. Moreover, the robust margin profile supports the company’s ability to weather short‑term disruptions, such as product withdrawals or regulatory delays, without compromising its long‑term growth strategy.
Boston Scientific is aggressively expanding into high‑growth international markets, notably China and Japan, where it has secured NMPA approval for the FARAWAVE NAV system and obtained persistent AF indications in China. The firm’s domestic EP market, already achieving approximately 80 % PFA penetration, indicates a near‑saturation point that drives clinicians to seek more advanced solutions, such as the newly approved FARAPOINT catheter. These geographic strides diversify the company’s revenue base, reduce dependence on any single market, and provide a buffer against regional economic or regulatory fluctuations. Consequently, the firm is well‑positioned to sustain its growth trajectory even if domestic markets face headwinds.

Bear case

During the Q&A, management conceded that the EP segment experienced sequential flatness and that competitors are launching similar technologies, implying a potential erosion of market share. They specifically acknowledged that the EP market may shrink from 80 % to 70 % penetration over time, suggesting that the current high adoption rate could be a temporary peak. This admission signals that the company’s 15 % organic growth target for 2026 may be overly optimistic, especially if competitors capitalize on new device launches to capture a larger slice of the EP market. If share loss materializes, the company’s ability to sustain high margin growth could be compromised, eroding investor confidence.
Watchman sales fell slightly below consensus, largely driven by weaker U.S. demand and the absence of a concrete plan to counter this slowdown. The company did not articulate a robust strategy to address potential reimbursement changes or to stimulate physician adoption, leaving a critical growth engine exposed. Should the Watchman device fail to achieve the anticipated adoption boost from the upcoming CHAMPION trial, the firm would lose a key revenue driver that underpins its cardiovascular portfolio. This scenario would force the company to rely more heavily on its EP segment and newer acquisitions, increasing concentration risk.
Product removals, including the withdrawal of certain AXIOS device sizes and the discontinuation of ACURATE, are expected to impose short‑term revenue losses and operational disruptions. Management projected a 150‑basis‑point hit in Q1 2026, which could materially compress margins during the first half of the year. These removals also risk eroding market confidence in the company’s product quality and could delay the launch of subsequent devices. If these issues are not fully resolved, they may create a persistent negative perception that hampers future sales and hinders the firm’s ability to secure favorable pricing agreements.
Integration risk from the pending acquisitions of Penumbra and Valencia remains significant. Neither deal has closed, and both are subject to regulatory, cultural, and operational integration challenges that could delay or dilute expected synergies. If integration stalls, the projected cost savings and revenue enhancements may not materialize, thereby reducing the overall upside. Additionally, the acquisitions introduce new debt and liquidity pressure, which could constrain the firm’s ability to invest in research and development or fund share‑repurchase programs, potentially impacting shareholder returns.
The company’s heavy reliance on high‑growth segments such as EP and Watchman exposes it to regulatory and reimbursement volatility. Both product lines face evolving payer policies and CMS coverage decisions that could curtail volumes if new guidelines become more restrictive. Increased competition from rivals offering similar or superior technologies further intensifies pricing pressure. These factors could erode pricing power, compress margins, and limit the company’s capacity to achieve the targeted double‑digit EPS growth, thereby posing a substantial risk to long‑term profitability.

During the Q&A, management conceded that the EP segment experienced sequential flatness and that competitors are launching similar technologies, implying a potential erosion of market share. They specifically acknowledged that the EP market may shrink from 80 % to 70 % penetration over time, suggesting that the current high adoption rate could be a temporary peak. This admission signals that the company’s 15 % organic growth target for 2026 may be overly optimistic, especially if competitors capitalize on new device launches to capture a larger slice of the EP market. If share loss materializes, the company’s ability to sustain high margin growth could be compromised, eroding investor confidence.
Watchman sales fell slightly below consensus, largely driven by weaker U.S. demand and the absence of a concrete plan to counter this slowdown. The company did not articulate a robust strategy to address potential reimbursement changes or to stimulate physician adoption, leaving a critical growth engine exposed. Should the Watchman device fail to achieve the anticipated adoption boost from the upcoming CHAMPION trial, the firm would lose a key revenue driver that underpins its cardiovascular portfolio. This scenario would force the company to rely more heavily on its EP segment and newer acquisitions, increasing concentration risk.
Product removals, including the withdrawal of certain AXIOS device sizes and the discontinuation of ACURATE, are expected to impose short‑term revenue losses and operational disruptions. Management projected a 150‑basis‑point hit in Q1 2026, which could materially compress margins during the first half of the year. These removals also risk eroding market confidence in the company’s product quality and could delay the launch of subsequent devices. If these issues are not fully resolved, they may create a persistent negative perception that hampers future sales and hinders the firm’s ability to secure favorable pricing agreements.
Integration risk from the pending acquisitions of Penumbra and Valencia remains significant. Neither deal has closed, and both are subject to regulatory, cultural, and operational integration challenges that could delay or dilute expected synergies. If integration stalls, the projected cost savings and revenue enhancements may not materialize, thereby reducing the overall upside. Additionally, the acquisitions introduce new debt and liquidity pressure, which could constrain the firm’s ability to invest in research and development or fund share‑repurchase programs, potentially impacting shareholder returns.
The company’s heavy reliance on high‑growth segments such as EP and Watchman exposes it to regulatory and reimbursement volatility. Both product lines face evolving payer policies and CMS coverage decisions that could curtail volumes if new guidelines become more restrictive. Increased competition from rivals offering similar or superior technologies further intensifies pricing pressure. These factors could erode pricing power, compress margins, and limit the company’s capacity to achieve the targeted double‑digit EPS growth, thereby posing a substantial risk to long‑term profitability.

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	161.43 Bn	24.86	3.64	12.93 Bn
2	SYK	Stryker Corp	125.09 Bn	38.55	4.98	15.86 Bn
3	MDT	Medtronic plc	105.13 Bn	22.78	2.96	28.07 Bn
4	BSX	Boston Scientific Corp	88.11 Bn	30.21	4.39	11.44 Bn
5	EW	Edwards Lifesciences Corp	46.61 Bn	43.80	7.68	0.60 Bn
6	PHG	Koninklijke Philips Nv	31.54 Bn	26.82	1.57	9.41 Bn
7	DXCM	Dexcom Inc	24.43 Bn	29.12	5.24	-
8	STE	STERIS plc	21.57 Bn	30.27	3.70	1.90 Bn

Research Tools